Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Allarity Therapeutics, Inc. (ALLR) has issued an update.
Allarity Therapeutics, Inc. has announced exciting progress in its Phase 2 clinical trial for stenoparib, revealing that several patients with advanced recurrent ovarian cancer have been successfully treated for over 30 weeks. This milestone indicates promising potential for the drug and showcases the company’s commitment to advancing cancer treatment.
For an in-depth examination of ALLR stock, go to TipRanks’ Stock Analysis page.
